Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Singer

Showing results (271-280 of 313) with videos related to

Pageof 32
Sort By:
European Heart Journal|March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trialJonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
JACC. Clinical Electrophysiology|September 19, 2024
Atrial Fibrillation Burden on a 14-Day ECG Monitor: Findings From the GUARD-AF Trial Screening ArmDaniel E Singer, Steven J Atlas, Alan S Go, et al.
Circulation|December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohortsJonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal|October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trialKenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
Journal of the American College of Cardiology|September 4, 2024
Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke PreventionRenato D Lopes, Steven J Atlas, Alan S Go, et al.
Heart (British Cardiac Society)|June 8, 2018
Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillationMichael T Durheim, DaJuanicia N Holmes, Rosalia G Blanco, et al.
American Heart Journal|February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AFVanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Circulation|September 11, 2013
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts"Jonathan P Piccini, Susanna R Stevens, Yuchiao Chang, et al.
Circulation. Cardiovascular Quality and Outcomes|May 17, 2019
Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life ScoreDaJuanicia N Holmes, Jonathan P Piccini, Larry A Allen, et al.
Pageof 32

Showing results (271-280 of 313) with videos related to

Sort By:
Pageof 32
European Heart Journal|March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trialJonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
JACC. Clinical Electrophysiology|September 19, 2024
Atrial Fibrillation Burden on a 14-Day ECG Monitor: Findings From the GUARD-AF Trial Screening ArmDaniel E Singer, Steven J Atlas, Alan S Go, et al.
Circulation|December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohortsJonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal|October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trialKenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
Journal of the American College of Cardiology|September 4, 2024
Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke PreventionRenato D Lopes, Steven J Atlas, Alan S Go, et al.
Heart (British Cardiac Society)|June 8, 2018
Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillationMichael T Durheim, DaJuanicia N Holmes, Rosalia G Blanco, et al.
American Heart Journal|February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AFVanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Circulation|September 11, 2013
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts"Jonathan P Piccini, Susanna R Stevens, Yuchiao Chang, et al.
Circulation. Cardiovascular Quality and Outcomes|May 17, 2019
Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life ScoreDaJuanicia N Holmes, Jonathan P Piccini, Larry A Allen, et al.
Pageof 32